Personal Genome Diagnostics
Total Raised
$260.27MInvestors Count
20Deal Terms
3Funding, Valuation & Revenue
13 Fundings
Personal Genome Diagnostics has raised $260.27M over 13 rounds.
Personal Genome Diagnostics's latest funding round was a Acquired for on December 23, 2021.
Personal Genome Diagnostics's latest post-money valuation is from December 2021.
Sign up for a free demo to see Personal Genome Diagnostics's valuations in December 2021 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/23/2021 | Acquired | 12 | ||||
2/10/2021 | Series C | $103M | TD Cowen, Catalio Capital Management, Innovatus Capital Partners, Kern Capital Management, NEA, Northpond Ventures, PFM Health Sciences, Rock Springs Capital, Sands Capital, Vensana Capital, and Windham Venture Partners | 15 | ||
5/26/2020 | Debt - III | $2.75M | Undisclosed Investors | 1 | ||
4/27/2020 | Loan - II | |||||
6/24/2019 | Debt - II |
Date | 12/23/2021 | 2/10/2021 | 5/26/2020 | 4/27/2020 | 6/24/2019 |
|---|---|---|---|---|---|
Round | Acquired | Series C | Debt - III | Loan - II | Debt - II |
Amount | $103M | $2.75M | |||
Investors | TD Cowen, Catalio Capital Management, Innovatus Capital Partners, Kern Capital Management, NEA, Northpond Ventures, PFM Health Sciences, Rock Springs Capital, Sands Capital, Vensana Capital, and Windham Venture Partners | Undisclosed Investors | |||
Valuation | |||||
Revenue | |||||
Sources | 12 | 15 | 1 |
Personal Genome Diagnostics Deal Terms
3 Deal Terms
Personal Genome Diagnostics's deal structure is available for 3 funding rounds, including their Acquired from December 23, 2021.
Round | Acquired | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired | |||||||||||||||
Series B | |||||||||||||||
Series A |
Personal Genome Diagnostics Investors
20 Investors
Personal Genome Diagnostics has 20 investors. Labcorp invested in Personal Genome Diagnostics's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
12/23/2021 | 12/23/2021 | 1 Acquired | Corporation | North Carolina | ||
10/28/2015 | 2/10/2021 | 3 Series A, Series B (2017), Series C (2021) | Venture Capital | New York | ||
10/28/2015 | 2/10/2021 | 3 Series A, Series B (2017), Series C (2021) | Venture Capital | California | ||
Debt & Specialty Finance | New York | |||||
Asset/Investment Management | New York |
First funding | 12/23/2021 | 10/28/2015 | 10/28/2015 | ||
|---|---|---|---|---|---|
Last Funding | 12/23/2021 | 2/10/2021 | 2/10/2021 | ||
Investor | |||||
Rounds | 1 Acquired | 3 Series A, Series B (2017), Series C (2021) | 3 Series A, Series B (2017), Series C (2021) | ||
Board Seats | |||||
Type | Corporation | Venture Capital | Venture Capital | Debt & Specialty Finance | Asset/Investment Management |
Location | North Carolina | New York | California | New York | New York |
Compare Personal Genome Diagnostics to Competitors
Human Longevity is a genomics-based health intelligence company that analyzes large-scale genomic and phenotypic data. The company provides services such as health assessments aimed at identifying diseases. Human Longevity serves the healthcare sector, focusing on personalized health information and disease awareness. It was founded in 2013 and is based in San Diego, California.
Protean BioDiagnostics specializes in laboratory diagnostic tools within the healthcare sector, focusing on cancer diagnostics and genetic testing. The company offers a cancer profiling system, Protean MAPS4, which provides results and oncology guidance, as well as telemedicine services and AI clinical trial matching. Protean BioDiagnostics serves the healthcare industry, including physicians, hospitals, and research institutions. It was founded in 2017 and is based in Tampa, Florida.
InsideTracker provides health analysis and wellness services in the health and wellness sector. The company offers services that analyze blood biomarkers to provide nutrition, exercise, and supplement recommendations based on data. InsideTracker serves individuals looking for insights related to their health and fitness. It was founded in 2009 and is based in Cambridge, Massachusetts.
Everlywell operates as a digital health company providing at-home health testing and virtual healthcare services. The company offers various laboratory test kits that provide health insights based on biomarkers, including tests for food sensitivities, sexually transmitted infections (STIs), hormone levels, and thyroid function. It was founded in 2015 and is based in Austin, Texas.
BiogeniQ conducts DNA testing in the healthcare sector, concentrating on pharmacogenomics and nutritional genomics. The company provides genetic tests that analyze individual responses to medications and dietary needs. BiogeniQ serves patients, healthcare professionals, insurance companies, and businesses interested in employee health management. It was founded in 2013 and is based in Brossard, Quebec.
Color specializes in genetic testing and health services. It focuses on early detection and management of cancer and hereditary diseases. The company offers genetic screenings to assess the risk for hereditary cancer and heart conditions, as well as services to understand medication responses, aiming to facilitate preventative health measures and personalized care plans. Color primarily serves employers, health plans, unions, and clinicians, providing them with tools to manage the health of their populations. Color was formerly known as Color Genomics. It was founded in 2014 and is based in Burlingame, California.
Loading...